Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 498 participants.
Also called NCT01922089
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 498 participants
- Sponsor
- Registry
-
NCT01922089 -
2013-001835-33
-
- Other papers using this trial's data
- Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study
- Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Finland, Germany, Hungary, Italy, Puerto Rico, Slovakia, Spain, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01922089. Randomized; quadruple masking; primary purpose treatment. Start 2013-11 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2015-10-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
- Acronym
- TITRATION
- Intervention (Drug)
- LCZ696
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01922089- Content hash
599c60e0811157c5f1608805c5b27f878623aa22a50043757f3864753317b3db